Table 2.
Differential expression of selected genes between pancreatic cancer (PC) patients and control
| Marker | Previous studya | Present study | |||||
|---|---|---|---|---|---|---|---|
| (PC/Normal) | (PC/Normal) | (Early PC/Normal) | (Late PC Normal) | (PC/CP) | (Early PC/CP) | (Late PC/CP) | |
| Anxa3b | 1.79 | 1.13 | 0.87 | 1.40 | 0.89 | 0.68 | 1.09 |
| Arg1b | 2.11 | 1.49 | 1.14 | 1.83 | 1.33 | 1.02 | 1.64 |
| Ca5bb | 0.62 | 0.57 | 0.56 | 0.58 | 0.33 | 0.32 | 0.34 |
| F5b | 1.59 | 0.99 | 0.70 | 1.31 | 0.65 | 0.46 | 0.86 |
| SSBP2b | 0.69 | 0.79 | 0.80 | 0.78 | 0.62 | 0.62 | 0.61 |
| TBC1D8b | 1.44 | 1.54 | 0.92 | 2.19 | 2.10 | 1.26 | 2.99 |
| MUC1 | 1.00 | 0.96 | 1.05 | 1.03 | 0.98 | 1.07 | |
| MUC1 | 1.17 | 1.15 | 1.19 | 0.94 | 0.93 | 0.96 | |
| NGAL | 1.02 | 1.03 | 1.01 | 0.87 | 0.88 | 0.86 | |
| MIC1 | 0.84 | 0.76 | 0.93 | 0.59 | 0.53 | 0.66 | |
a
The previous study did not divide samples into early PC and late PC but rather grouped all PC together. Furthermore, it contained only 6 out of 35 samples that were considered early PC.
b
Genes chosen for validation in the expanded patient set.